Abstract: The present invention provides a method for increasing production of a metabolite by a non-naturally occurring methylotroph, comprising growing the non-naturally occurring methylotroph in a medium comprising methanol. Expression of one or more native genes in the non-naturally occurring methylotroph is changed. Also provided are the non-naturally occurring methylotroph and preparation thereof.

Abstract: Compounds having General Formula (I) or General Formula (II): in which R1 is chosen from C1 to C10 aliphatic or heteroaliphatic groups, optionally substituted with one or more aryl groups, substituted aryl groups, heteroaryl groups, substituted heteroaryl groups, or combination thereof, R2 is chosen from aromatic moieties, substituted aromatic moieties, heteroaromatic moieties, substituted heteroaromatic moieties, and coumarin; R3 is chosen from —H, C1 to C10 aliphatic or heteroaliphatic groups, phenyl, or substituted phenyl, wherein the aliphatic or heteroaliphatic groups are optionally substituted with one or more phenyl groups, aryl groups, heteroaryl groups, substituted heteroaryl groups, or combination thereof, and wherein the aliphatic or heteroaliphatic groups are optionally bonded to R2 to form a ring; X is S or O; and Y is S or NH, may be used in pharmaceutical compositions that modify of biological signaling processes or as reagents for biological assays.

Abstract: Methods and systems for efficient culturing of algae in open ponds are described.

Abstract: A variety of targeting moiety peptide epitope complexes (TPECs) are described in different embodiments. In each of the embodiments, however, a targeting moiety may be used to deliver the TPEC to an area of unwanted cells, allowing for a therapeutic effect to be delivered locally. The TPEC also contains a plurality of T-cell epitopes. The TPEC further comprises cleavage sites that release the T-cell epitopes from the targeting agent, and in some embodiments from each other, when they are in the microenvironment of the unwanted cells. Although the arrangement and number of T-cell epitopes varies in different embodiments described herein, once cleaved from the targeting agent (and any neighboring T-cell epitopes), the T-cell epitopes function by stimulating an immune response against the unwanted cells.

Abstract: In general, the present invention is directed to processes for separating a vapor comprising a first component and a second component using high-pressure density-driven separation. The present invention further relates to various processes for the capture of carbon dioxide. In particular, various processes of the present invention relate to the separation of carbon dioxide from flue gas of combustion processes. The invention also applies to upgrading fuel gases containing carbon dioxide. The invention also applies to separation of hydrogen from fuel gas vapor solutions.

Abstract: An intravascular cell therapy device comprises a scaffold (2, 12) that is radially adjustable between a contracted orientation suitable for transluminal delivery to a vascular locus and an expanded orientation, and a biodegradable matrix provided on at least a portion of the scaffold that is suitable for seeding with cells and degrades in a vascular environment. The scaffold is configured to have a distal piercing tip (5) when in a deployed orientation. The scaffold comprises a plurality of sidewall panels (3, 13, 14) arranged around a longitudinal axis of the scaffold, and adjustable couplings (4) between the panels configured for adjustment between an expanded configuration and a contracted orientation, and in which each sidewall panel comprises a matrix suitable for seeding with cells.

Abstract: Methods, media, and systems for detecting an anomalous sequence of function calls are provided. The methods can include compressing a sequence of function calls made by the execution of a program using a compression model; and determining the presence of an anomalous sequence of function calls in the sequence of function calls based on the extent to which the sequence of function calls is compressed. The methods can further include executing at least one known program; observing at least one sequence of function calls made by the execution of the at least one known program; assigning each type of function call in the at least one sequence of function calls made by the at least one known program a unique identifier; and creating at least part of the compression model by recording at least one sequence of unique identifiers.

Abstract: A medical image analysis method applying machine learning and system thereof are provided. The medical image analysis system includes a cloud server and an electronic device. The cloud server stores a deep learning module and an artificial intelligence model. The medical image analysis method includes the following steps. Correction data is inputted to the deep learning module so that the deep learning module corrects the artificial intelligence model according to the correction data to generate a corrected artificial intelligence model. Furthermore, medical image data is inputted to the electronic device, and the electronic device provides the medical image data to the cloud server to analyze the medical image data through the corrected artificial intelligence model and generates analysis result data.

Abstract: An expression system, comprising: a first nucleic acid molecule having a cell-specific promoter; a second nucleic acid molecule which encodes a transcriptional activator; a third nucleic acid molecule having a first recognition sequence of the transcriptional activator; a fourth nucleic acid molecule having a first promoter and a first regulatory element; a fifth nucleic acid molecule which encodes a first regulatory protein; a sixth nucleic acid molecule having a second recognition sequence of the transcriptional activator; a seventh nucleic acid molecule having a second promoter and a second regulatory element; an eighth nucleic acid molecule which encodes a second regulatory protein; as well as a ninth nucleic acid molecule which is configured to conditionally inhibit the expression of the first regulatory protein, and a tenth nucleic acid molecule which is configured to conditionally inhibit the expression of the second regulatory protein; the first regulatory element is adapted to inhibit the function of

Abstract: A therapeutic treatment for preventing or reducing the formation of fibrosis comprising administering to a patient a UTX or JMJD3 inhibitor that are effective in preventing or reducing fibrosis in situations wherein access to an injury or dysmorphogenetic tissues before the fibrotic process becomes established in the tissues.

Abstract: Methods are provided for the isolation, expansion, enrichment, and transplantation of endothelial stem cells from blood vessels and induced pluripotent stem cells via the use of ABCG2 cell surface marker. The ability of the endothelial stem cells to expand in vitro and be subsequently implanted in vivo to generate new blood vessels provides a therapeutic hope for patients with numerous cardiovascular disorders (peripheral arterial disease, critical limb ischemia, ischemic retinopathies, acute ischemic injury to kidney, and myocardial infarction) where the lack of sufficient blood vessel forming ability in the patient limits their regenerative capacity.

Abstract: The disclosure relates to methods and compositions for regulating expression of DUX4. Specifically, the disclosure provides a recombinant gene editing complex comprising: a recombinant gene editing protein; and, a nucleic acid encoding a guide RNA (gRNA) that specifically hybridizes to a target nucleic acid sequence encoding a D4Z4 macrosatellite repeat region, wherein binding of the complex to the target nucleic acid sequence results in inhibition of DUX4 gene expression. In some aspects, methods described by the disclosure are useful for treating a disease associated with aberrant DUX4 expression (e.g., facioscapulohumeral muscular dystrophy, FSHD).

Abstract: Provided are novel TDP-43-specific binding molecules including polypeptides such as human antibodies, as well as fragments, derivatives and variants thereof. Also provided are methods related to these TDP-43 specific binding molecules. Assays, kits, and solid supports related to TDP-43-specific binding molecules, including polypeptides such as, human antibodies are also disclosed. The TDP-43-specific binding molecule, antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for TDP-43 targeted immunotherapy and diagnosis, respectively.

Abstract: Audio (noise source) is output as a cancellation sound through a variable filter and a first filter, and transmitted to the second filter. A subtractor subtracts an output of a second filter from an output of a microphone, and an adaptive algorithm execution unit updates a transfer function of the variable filter so that the subtracted result becomes zero (0). A transfer function A for the first filter is a transfer function which can cancel noise at a position of a user's ear by setting, as the cancellation sound, a sound obtained by applying the transfer function A to audio at the time of learning, and a transfer function B for the second filter is a transfer function which can eliminate, for the cancellation sound, a difference between a sound obtained by applying the transfer function B to audio and the output of the microphone.

Abstract: A composition for inhibiting sodium leakage channel (NALCN), including as an active ingredient N-benzhydryl quinuclidine (NBQN) or a N-benzhydryl quinuclidine derivative represented by the following Formula 1, wherein in the following Formula 1, R is an unsubstituted or substituted benzyl group

Abstract: This disclosure relates to modulators of liver receptor homologue 1 (LRH-1) and methods of managing disease and conditions related thereto. In certain embodiments, modulators are derivatives of hexahydropentalene. In certain embodiments, this disclosure relates to methods of treating or preventing cancer, diabetes, or cardiovascular disease by administering an effective amount of a hexahydropentalene derivative disclosed herein.

Abstract: Disclosed are novel genetic arrays for use in the molecular detection of multiple Salmonella serovars, common food-borne and water-borne pathogens. The arrays may be used to simultaneously detect multiple food safety Salmonella serovars. The multiplex-detection methods have improved sensitivity and specificity for the detection of multiple high-impact food-borne pathogens simultaneously. Real-time PCR assaying techniques using such serovars include microarrays.

Abstract: A pressure sensor system is provided. In another aspect, a wireless intraocular pressure sensor includes a deformable or stretchable inductor. A further aspect of an intraocular pressure sensing system includes a deformable inductor sized to contact an eye. Another aspect provides an organ pressure sending system including a passive inductor with a wavy, serpentine or undulating shape.

Abstract: Devices, systems, and methods for repositioning organs, such as the rectum, during radiation therapy treatments, are described.

Abstract: A palm-type mechanical gripper with variable-position and rotatable fingers and a crank-rocker-slider parallel mechanism adopts crank-rocker-slider mechanisms and three identical flexible plate spring fingers, wherein one finger is fixed, and the other two fingers can rotate and move to achieve translational motions and are respectively and symmetrically installed on connecting rods or rockers on left and right sides. The crank-rocker-slider mechanism on the left side is an active driving structure and is driven by two stepping motors to respectively generate angular displacement of cranks and linear movement of sliders. The crank-rocker-slider mechanism on the right side is a driven mechanism and is driven at a constant speed by a pair of gears. The eccentricities of the cranks, the positions and angles of the two fingers respectively on the two connecting rods or rockers and the position of the other fixed finger can be changed through manual adjustment.